What's Happening?
A recent study, the Tirzepatide and Resistance Exercise (T-REx) trial, published in Nature Medicine on November 9, 2026, indicates that resistance training can significantly reduce lean mass loss in adults using tirzepatide, a GLP-1 medication. The trial involved
120 sedentary adults, aged 50 to 70, with overweight or obesity but without diabetes or cardiovascular disease. Participants were divided into two groups: one received tirzepatide alone, and the other received tirzepatide combined with supervised resistance training three times a week for 40 weeks. While both groups experienced similar weight and fat loss, the group that incorporated resistance training lost less lean soft tissue (3.57 kg vs. 4.67 kg) and showed increased strength across various exercises, whereas the medicine-only group experienced a decrease in strength. The training program progressed through five 8-week phases, from light technique work to vigorous strength and hypertrophy training, with high adherence.
Why It's Important?
This research holds significant implications for the growing number of individuals in the U.S. prescribed GLP-1 medications for weight management. The findings suggest that combining these medications with resistance training can help preserve muscle mass, which is crucial for overall health, metabolism, and functional independence, especially in older adults. Losing lean mass can lead to decreased strength, reduced mobility, and a lower metabolic rate, potentially undermining some long-term health benefits of weight loss. For personal trainers and healthcare providers, the study emphasizes the importance of integrating structured exercise, particularly strength training, into treatment plans for clients on GLP-1s. This could lead to improved patient outcomes, better body composition, and a more sustainable approach to weight management, potentially influencing public health guidelines and fitness industry practices.
What's Next?
The study's lead investigator, Winthrop Professor Danny Green, highlighted that while GLP-1 medicines are 'blockbuster drugs,' they are 'not the full toolkit,' underscoring the need for a comprehensive approach that includes exercise. Healthcare providers are encouraged to consider prescribing resistance training alongside GLP-1 medications. Personal trainers working with clients on these medications should consult with the client's prescriber to understand any exercise limitations and ensure their training programs align with medical advice. The findings may prompt further research into optimal exercise protocols for GLP-1 users and could lead to updated guidelines for fitness professionals regarding their scope of practice when advising clients on medication. The study also reinforces the need for clear communication between clients, trainers, and medical professionals to ensure safe and effective health outcomes.
Beyond the Headlines
The T-REx trial sheds light on a critical aspect of weight loss: the quality of weight lost. While GLP-1 medications are highly effective for reducing body weight, the accompanying loss of lean mass has been a concern. This study provides a scientific basis for mitigating that concern through targeted intervention. It also highlights the evolving role of personal trainers, who increasingly need to navigate complex client health profiles, including those on prescription medications. The distinction between exercise advice and medical advice becomes even more crucial, emphasizing the need for trainers to possess accredited certifications and adhere strictly to their scope of practice. This development could foster greater collaboration between the medical and fitness communities, leading to more integrated and holistic patient care models that prioritize both weight loss and the preservation of functional strength and muscle mass.
